The FDA’s Pharmacy Compounding Advisory Committee voted narrowly on July 23, 2026 (8-6 with one abstention) to recommend BPC-157 for the 503A Bulks List after reviewing it for ulcerative colitis use, overriding staff opposition. This followed the substance’s removal from Category 2 in April 2026 amid broader policy shifts on peptides. Category 1 status would permit patient-specific compounding by 503A pharmacies during ongoing evaluation, but requires formal notice-and-comment rulemaking that typically spans eight to twelve months or longer. No final Federal Register action placing BPC-157 in Category 1 has occurred as of mid-August 2026. Traders are therefore focused on the pace of any subsequent FDA rulemaking announcement, potential docket comments, and whether the agency adopts the advisory recommendation before key deadlines in the relevant prediction markets.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedNEW
Aug 31, 2026
August 31, 2026
12%
December 31, 2026
55%
$2,648 Vol.
August 31, 2026
$942 Vol.
12%
December 31, 2026
$1,706 Vol.
55%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA’s Pharmacy Compounding Advisory Committee voted narrowly on July 23, 2026 (8-6 with one abstention) to recommend BPC-157 for the 503A Bulks List after reviewing it for ulcerative colitis use, overriding staff opposition. This followed the substance’s removal from Category 2 in April 2026 amid broader policy shifts on peptides. Category 1 status would permit patient-specific compounding by 503A pharmacies during ongoing evaluation, but requires formal notice-and-comment rulemaking that typically spans eight to twelve months or longer. No final Federal Register action placing BPC-157 in Category 1 has occurred as of mid-August 2026. Traders are therefore focused on the pace of any subsequent FDA rulemaking announcement, potential docket comments, and whether the agency adopts the advisory recommendation before key deadlines in the relevant prediction markets.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Market Opened: Jun 22, 2026, 10:10 PM ET
Volume
$2,648End Date
Dec 31, 2026Market Opened
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA’s Pharmacy Compounding Advisory Committee voted narrowly on July 23, 2026 (8-6 with one abstention) to recommend BPC-157 for the 503A Bulks List after reviewing it for ulcerative colitis use, overriding staff opposition. This followed the substance’s removal from Category 2 in April 2026 amid broader policy shifts on peptides. Category 1 status would permit patient-specific compounding by 503A pharmacies during ongoing evaluation, but requires formal notice-and-comment rulemaking that typically spans eight to twelve months or longer. No final Federal Register action placing BPC-157 in Category 1 has occurred as of mid-August 2026. Traders are therefore focused on the pace of any subsequent FDA rulemaking announcement, potential docket comments, and whether the agency adopts the advisory recommendation before key deadlines in the relevant prediction markets.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$2,648End Date
Dec 31, 2026Market Opened
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The FDA’s Pharmacy Compounding Advisory Committee voted narrowly on July 23, 2026 (8-6 with one abstention) to recommend BPC-157 for the 503A Bulks List after reviewing it for ulcerative colitis use, overriding staff opposition. This followed the substance’s removal from Category 2 in April 2026 amid broader policy shifts on peptides. Category 1 status would permit patient-specific compounding by 503A pharmacies during ongoing evaluation, but requires formal notice-and-comment rulemaking that typically spans eight to twelve months or longer. No final Federal Register action placing BPC-157 in Category 1 has occurred as of mid-August 2026. Traders are therefore focused on the pace of any subsequent FDA rulemaking announcement, potential docket comments, and whether the agency adopts the advisory recommendation before key deadlines in the relevant prediction markets.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions